363 related articles for article (PubMed ID: 30553949)
1. Improving in vitro photodynamic therapy through the development of a novel iron chelating aminolaevulinic acid prodrug.
Curnow A; Perry A; Wood M
Photodiagnosis Photodyn Ther; 2019 Mar; 25():157-165. PubMed ID: 30553949
[TBL] [Abstract][Full Text] [Related]
2. An experimental investigation of a novel iron chelating protoporphyrin IX prodrug for the enhancement of photodynamic therapy.
Anayo L; Magnussen A; Perry A; Wood M; Curnow A
Lasers Surg Med; 2018 Jul; 50(5):552-565. PubMed ID: 29603761
[TBL] [Abstract][Full Text] [Related]
3. Experimental investigation of a combinational iron chelating protoporphyrin IX prodrug for fluorescence detection and photodynamic therapy.
Magnussen A; Reburn C; Perry A; Wood M; Curnow A
Lasers Med Sci; 2022 Mar; 37(2):1155-1166. PubMed ID: 34218351
[TBL] [Abstract][Full Text] [Related]
4. Biochemical manipulation via iron chelation to enhance porphyrin production from porphyrin precursors.
Curnow A; Pye A
J Environ Pathol Toxicol Oncol; 2007; 26(2):89-103. PubMed ID: 17725535
[TBL] [Abstract][Full Text] [Related]
5. Photodynamic anticancer activity evaluation of novel 5-aminolevulinic acid and 3-hydroxypyridinone conjugates.
Zhang J; Yuan S; Fan M; Wang K; Guo J; Zang A; Ren J; Su W; Zhang C; Xie Y
Bioorg Med Chem; 2024 May; 105():117726. PubMed ID: 38626642
[TBL] [Abstract][Full Text] [Related]
6. The efficacy of an iron chelator (CP94) in increasing cellular protoporphyrin IX following intravesical 5-aminolaevulinic acid administration: an in vivo study.
Chang SC; MacRobert AJ; Porter JB; Bown SG
J Photochem Photobiol B; 1997 Apr; 38(2-3):114-22. PubMed ID: 9203372
[TBL] [Abstract][Full Text] [Related]
7. The effects of protoporphyrin IX-induced photodynamic therapy with and without iron chelation on human squamous carcinoma cells cultured under normoxic, hypoxic and hyperoxic conditions.
Blake E; Allen J; Curnow A
Photodiagnosis Photodyn Ther; 2013 Dec; 10(4):575-82. PubMed ID: 24284114
[TBL] [Abstract][Full Text] [Related]
8. The hydroxypyridinone iron chelator CP94 can enhance PpIX-induced PDT of cultured human glioma cells.
Blake E; Curnow A
Photochem Photobiol; 2010; 86(5):1154-60. PubMed ID: 20573043
[TBL] [Abstract][Full Text] [Related]
9. The hydroxypyridinone iron chelator CP94 increases methyl-aminolevulinate-based photodynamic cell killing by increasing the generation of reactive oxygen species.
Dogra Y; Ferguson DCJ; Dodd NJF; Smerdon GR; Curnow A; Winyard PG
Redox Biol; 2016 Oct; 9():90-99. PubMed ID: 27454766
[TBL] [Abstract][Full Text] [Related]
10. Enhancement of 5-aminolaevulinic acid-induced photodynamic therapy in normal rat colon using hydroxypyridinone iron-chelating agents.
Curnow A; McIlroy BW; Postle-Hacon MJ; Porter JB; MacRobert AJ; Bown SG
Br J Cancer; 1998 Nov; 78(10):1278-82. PubMed ID: 9823966
[TBL] [Abstract][Full Text] [Related]
11. Direct comparison of delta-aminolevulinic acid and methyl-aminolevulinate-derived protoporphyrin IX accumulations potentiated by desferrioxamine or the novel hydroxypyridinone iron chelator CP94 in cultured human cells.
Pye A; Curnow A
Photochem Photobiol; 2007; 83(3):766-73. PubMed ID: 17576385
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of methyl-aminolevulinate photodynamic therapy by iron chelation with CP94: an in vitro investigation and clinical dose-escalating safety study for the treatment of nodular basal cell carcinoma.
Pye A; Campbell S; Curnow A
J Cancer Res Clin Oncol; 2008 Aug; 134(8):841-9. PubMed ID: 18239941
[TBL] [Abstract][Full Text] [Related]
13. Iron chelation promotes 5-aminolaevulinic acid-based photodynamic therapy against oral tongue squamous cell carcinoma.
Qin J; Zhou C; Zhu M; Shi S; Zhang L; Zhao Y; Li C; Wang Y; Wang Y
Photodiagnosis Photodyn Ther; 2020 Sep; 31():101907. PubMed ID: 32619712
[TBL] [Abstract][Full Text] [Related]
14. An in vitro comparison of the effects of the iron-chelating agents, CP94 and dexrazoxane, on protoporphyrin IX accumulation for photodynamic therapy and/or fluorescence guided resection.
Blake E; Allen J; Curnow A
Photochem Photobiol; 2011; 87(6):1419-26. PubMed ID: 21834866
[TBL] [Abstract][Full Text] [Related]
15. Design, synthesis and biological evaluation of 5-aminolaevulinic acid/3-hydroxypyridinone conjugates as potential photodynamic therapeutical agents.
Zhu CF; Battah S; Kong X; Reeder BJ; Hider RC; Zhou T
Bioorg Med Chem Lett; 2015 Feb; 25(3):558-61. PubMed ID: 25556100
[TBL] [Abstract][Full Text] [Related]
16. A hydroxypyridinone (CP94) enhances protoporphyrin IX formation in 5-aminolaevulinic acid treated cells.
Bech O; Phillips D; Moan J; MacRobert AJ
J Photochem Photobiol B; 1997 Nov; 41(1-2):136-44. PubMed ID: 9440321
[TBL] [Abstract][Full Text] [Related]
17. A quantitative assessment of protoporphyrin IX metabolism and phototoxicity in human skin following dose-controlled delivery of the prodrugs 5-aminolaevulinic acid and 5-aminolaevulinic acid-n-pentylester.
Gerscher S; Connelly JP; Beijersbergen Van Henegouwen GM; MacRobert AJ; Watt P; Rhodes LE
Br J Dermatol; 2001 May; 144(5):983-90. PubMed ID: 11359385
[TBL] [Abstract][Full Text] [Related]
18. Topical aminolaevulinic acid- and aminolaevulinic acid methyl ester-based photodynamic therapy with red and violet light: influence of wavelength on pain and erythema.
Mikolajewska P; Iani V; Juzeniene A; Moan J
Br J Dermatol; 2009 Nov; 161(5):1173-9. PubMed ID: 19785604
[TBL] [Abstract][Full Text] [Related]
19. The effect of an iron chelating agent on protoporphyrin IX levels and phototoxicity in topical 5-aminolaevulinic acid photodynamic therapy.
Choudry K; Brooke RC; Farrar W; Rhodes LE
Br J Dermatol; 2003 Jul; 149(1):124-30. PubMed ID: 12890205
[TBL] [Abstract][Full Text] [Related]
20. Peptide-targeted dendrimeric prodrugs of 5-aminolevulinic acid: A novel approach towards enhanced accumulation of protoporphyrin IX for photodynamic therapy.
Tewari KM; Dondi R; Yaghini E; Pourzand C; MacRobert AJ; Eggleston IM
Bioorg Chem; 2021 Apr; 109():104667. PubMed ID: 33611140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
